Reasons for discontinuation of prior anti-TNF (before enrolment in the RAPID-PsA study)
| Week 0 placebo (n=26) | Week 0 CZP 200 mg Q2W (n=31) | Week 0 CZP 400 mg Q4W (n=23) | |
|---|---|---|---|
| Prior anti-TNF exposure, n (%) | 26 (19.1) | 31 (22.5) | 23 (17.0)* |
| Adalimumab | 13 (9.6) | 10 (7.2) | 10 (7.4) |
| Etanercept | 9 (6.6) | 15 (10.9) | 8 (5.9) |
| Infliximab | 2 (1.5) | 5 (3.6) | 5 (3.7) |
| Golimumab | 2 (1.5) | 1 (0.7) | 1 (0.7) |
| Reason for discontinuation of prior anti-TNF, n (%) | |||
| Primary lack of response | 3 (11.5) | 2 (6.5) | 0 |
| Secondary loss of response | 8 (30.8) | 9 (29.0) | 6 (26.1) |
| Intolerance | 2 (7.7) | 5 (16.1) | 0 |
| Partial response | 1 (3.8) | 2 (6.5) | 3 (13.0) |
| Unknown | 0 | 0 | 1 (4.3) |
| Other | 12 (46.2) | 13 (41.9) | 13 (56.5) |
| Bicytopenia | 0 | 0 | 1 (4.3) |
| Bowel perforation | 0 | 0 | 1 (4.3) |
| Financial reasons | 4 (15.4) | 7 (22.6) | 5 (21.7) |
| Drug unavailable | 3 (11.5) | 1 (3.2) | 1 (4.3) |
| End of clinical evaluations | 3 (11.5) | 3 (9.7) | 1 (4.3) |
| Insurance reasons | 1 (3.8) | 1 (3.2) | 3 (13.0) |
| Painful injection site reactions | 0 | 1 (3.2) | 0 |
| Family planning reasons | 1 (3.8) | 0 | 0 |
| Preparation for surgery | 0 | 0 | 1 (4.3) |
Data shown for patients from the randomised set of patients from RAPID-PsA with prior anti-TNF exposure.
*One patient had past use of both adalimumab and etanercept.
CZP, certolizumab pegol; Q2W, every 2 weeks; TNF, tumour necrosis factor.